

Mongolia

Support for Vaccine: Inactivated Polio Virus This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Mongolia		
2. Vaccine grant number:	15-MNG-08h-Y, 1518-MNG-25b-X, 19-MNG-25b-X, 20-MNG-25b-X		
3. Date of Decision Letter:	30/09/2019		
4. Date of the Partnership Framework Agreement (PFA):	11/06/2014		
5. Programme title:	New Vaccine Support (NVS), Inactivated Polio Virus, Routine		
6. Vaccine type:	Inactivated Polio Virus		
7. Requested product presentation and formulation of vaccine:	Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID		
8. Programme Duration:¹	2015-2020		
9. Programme Budget (indicative):²	(subject to the terms of the PFA, if applicable)		
	2015-2019	2020	Total²
Programme Budget (US\$)	261,153	217,000	478,153
10. Vaccine introduction grant			
	Approval		
	Year	Grant Number	Amount (US\$)
	2015	15-MNG-08h-Y	100,000
	Disbursement		
	Disbursement date	Amount (US\$)	
	10 December, 2015	100,000	
11. Product switch grant:	Not applicable		
12. Indicative Annual Amounts:³	(subject to the terms of the PFA, if applicable)		
	2015-2019	2020	2021
Type of supplies to be purchased with Gavi funds			
Number of vaccine doses		80,000	-
Annual Amounts (US\$)	261,153	217,000	-
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
14. Self-procurement:	Not applicable		
15. Co-financing obligations:	Not applicable		
	Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.		

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

16. Operational support for campaigns: Not applicable

17. Additional Reporting Requirements:

	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> • Vaccine stock levels including buffer stock, by end of March; • Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. • Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2020</p> <p>15 May 2020</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>

18. Financial clarifications: Not applicable

19. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,
On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30 September 2019